Media Conference

The Latest Media Conference

Conference on FY 2023.12 Financial Results

Date:

February 01, 2024

Presentations:

FY2023 Overview and FY2024 Forecast
Dr. Osamu Okuda,
President & CEO
Overview of Development Pipeline
Tetsuya Yamaguchi,
Executive Vice President, Head of Foundation Medicine Unit
FY2023 Consolidated Financial Overview (Core)
Toshiaki Itagaki,
Director, Executive Vice President & CFO

Past Media Conferences

2023

  • Dec 12, 2023
    Chugai R&D Meeting
    Characteristics of Chugai’s Research to Early Development
    Tomoyuki Igawa Ph.D., Associate Vice President, Head of Translational Research Div.
    Chugai’s Mid-Size Molecule Drug Discovery
    Hitoshi Iikura Ph.D., Vice President, Head of Research Div.
  • Nov 30, 2023
    Information Meeting on PHESGO®
    Overview of PHESGO® Combination for Subcutaneous Injection MA/IN
    Yuji Habara,
    HER2 franchise Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Clinical Significance of PHESGO® in the Treatment of HER2-Positive Breast Cancer
    Naoki Hayashi, M.D., Ph.D.
    Professor and Chairman, Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine
  • Nov 20, 2023
    Sustainability Meeting
    Shared Value Creation Model for Chugai and Society
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Supervisory responsibility for Finance & Accounting, Corporate Communications and Procurement
    Case Study: Collaboration with Patient Organizations
    Hiroyuki Yamase,
    Head of Public Affairs Group External Affairs Dept.
    Sustainability and Risk Management
    Case Study: Preparation of a Digital Compliance System
    Junichi Ebihara,
    Executive Vice President
    Supervisory responsibility for Legal, Intellectual Property, General Affairs, Risk Management, Compliance and Quality & Regulatory Compliance
    Human Capital and Innovation
    Yoshiyuki Yano,
    Executive Vice President
    Supervisory responsibility for Human Resource Management and EHS
    Case Study: Promote the Success of Women
    Kaeko Sato,
    Head of Diversity Office Human Resources Management Dept.
  • Oct 24, 2023
    Conference on FY2023.12 Q3 Financial Results
    FY2023 Q3 Overview
    Dr. Osamu Okuda,
    President & CEO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
    FY2023 Q3 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
  • Sep 29, 2023
    Chugai DX Meeting
    Progress in CHUGAI DIGITAL
    Satoko Shisai,
    Executive Vice President, Head of Digital Transformation Unit
    Three Initiatives to Strengthen the Digital Platform

    Keisuke Ohara,
    Head of IT Solution Dept.

    Kazumitsu Kanatani,
    Head of Digital Strategy Dept.

    Status of Progress in the Insight Business
    Dr. Nobuya Ishii,
    Head of Science & Technology Intelligence Dept.
  • Jul 27, 2023
    Conference on FY2023.12 Q2 Financial Results
    FY2023 Q2 Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2023 Q2 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
  • Jul 18, 2023
    Chugai Life Science Park Yokohama Laboratory Tour
    Initiatives Underway at the New Research Facility Aimed at Creating Innovative New Drugs
    Dr. Hitoshi Iikura, Vice President
    Head of Research Division
    Expansion of Drug Discovery Research that Fuses Dry and Wet Research
    Dr. Atsushi Ohta,
    Head of Modality Technology Research Department
    Acceleration of Chugai Drug Discovery with 3D Structures Generated by Cryogenic Electron Microscopy (Cryo-EM)
    Dr. Takuya Torizawa
    Head of Protein Science Department
  • Apr 27, 2023
    Conference on FY 2023.12 Q1 Financial Results
    FY2023 Q1 Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2023 Q1 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
  • Feb 02, 2023
    Conference on FY 2022.12 Financial Results
    FY2022 Overview and FY2023 Forecast
    Dr. Osamu Okuda,
    President & CEO
    FY2022 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit

2022

  • Nov 08, 2022
    Chugai ESG Meeting
    Sustainability Management
    Toshiaki Itagaki, Director, Executive Vice President & CFO
    Chugai’s Governance and Issues Going Forward
    Masayuki Oku, Independent Outside Director
    Transformation Tasks in Materiality - Environment and Human Resources -
    Yoshiyuki Yano, Executive Vice President, Head of Human Resources Management Dept.
    Patient-Centric Business Activities - Medical Affairs -
    Dr. Kaori Ouchi, Vice President, Head of Medical Affairs Div.
  • Oct 24, 2022
    Conference on FY2022.12 3Q Financial Results
    FY2022 3Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2022 3Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
  • Jul 21, 2022
    Conference on FY2022.12 2Q Financial Results
    FY2022 2Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2022 2Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
  • Jun 24, 2022
    Information Meeting on Vabysmo®
    Overview of Vabysmo® Solution for Intravitreal Injection 120 mg/mL
    Masashi Kishida, Ph.D.,
    Vabysmo Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Clinical Significance of Vabysmo®
    Tomohiro Iida, M.D., Ph.D.,
    Professor & Chairman, Department of Ophthalmology, Tokyo Women’s Medical University
  • Apr 25, 2022
    1Q Results (Jan - Mar 2022) Conference Call
    FY2022 1Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2022 1Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Director, Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit
  • Feb 03, 2022
    Conference on FY2021.12 Financial Results
    FY2021 Overview and FY2022 Forecast
    Dr. Osamu Okuda,
    President & CEO
    FY2021 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Executive Vice President, Head of Project & Lifecycle Management Unit

2021

  • Dec 13, 2021
    Chugai R&D Meeting
    Chugai’s Research Policy/Chugai’s Mid-Size Molecule Drug Discovery
    Hitoshi Iikura Ph.D., Head of Research Div.
    Update on Antibody Engineering Technologies
    Tomoyuki Igawa Ph.D., Head of Translational Research Div.
  • Nov 16, 2021
    Chugai ESG Meeting
    Sustainability Management
    Motoo Ueno, Representative Director & Deputy Chairman
    Materiality and ESG Ratings
    Toshiaki Itagaki, Executive Vice President & CFO
    ESG in the Context of Growth Strategy Drug Development in Pursuit of Sustainable Healthcare
    Tsukasa Kusano, Vice President, Head of Clinical Development Div.
    ESG in the Context of Growth Strategy Global Environmental Initiatives (Pharmaceutical Technology)
    Shigehiro Yamada, Ph. D., Head of Sustainability Dept.
  • Oct 22, 2021
    3Q Results (Jan - Sep 2021) Conference Call
    FY2021 3Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2021 3Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Senior Vice President, Head of Project & Lifecycle Management Unit
  • Sep 27, 2021
    Information Meeting on Evrysdi®
    Overview of Evrysdi®
    Hideto Kodaira,
    Evrysdi Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Evrysdi®, a New Treatment Option for Spinal Muscular Atrophy (SMA): The First Oral SMA Drug
    Kayoko Saito, MD, PhD,
    Professor of Special Appointment, Institute of Medical Genetics, Tokyo Women’s Medical University
  • Sep 09, 2021
    Information Meeting on FoundationOne® Liquid CDx
    Product Overview
    Satoru Ito,
    Lifecycle Leader, Foundation Medicine Unit, Chugai Pharmaceutical Co., Ltd.
    Current Status of Cancer Genomic Medicine in Japan and Expectations for FoundationOne® Liquid CDx Cancer Genomic Profile
    Takayuki YOSHINO, MD, PhD,
    Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East (NCCE), Japan
  • Aug 26, 2021
    Information Meeting on RONAPREVE
    Striving to Develop Therapeutic Drugs for COVID-19
    Dr.Osamu Okuda,
    President & CEO, Chugai Pharmaceutical Co., Ltd.
    Product Overview of RONAPREVE Intravenous Infusion Set
    Satoshi Aida,
    Ph.D., RONAPREVE Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Confronting COVID-19
    Prof. Kazuhiro Tateda M.D., Ph.D.,
    Department of Microbiology and Infectious Disease, Toho University School of Medicine
  • Jul 26, 2021
    2Q Results (Jan - Jun 2021) Conference Call
    FY2021 2Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2021 2Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Senior Vice President, Head of Project & Lifecycle Management Unit
  • Jun 03, 2021
    Information Meeting on Polivy®
    Polivy® Intravenous Infusion 30mg/140mg
    Dr. Takaki Koga,
    POLIVY® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Treatment Options for Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Koji Izutsu, M.D., Ph.D.,
    Department of Hematology, National Cancer Center Hospital
  • Apr 22, 2021
    1Q Results (Jan - Mar 2021) Conference Call
    FY2021 1Q Overview
    Dr. Osamu Okuda,
    President & CEO
    FY2021 1Q Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Senior Vice President, Head of Project & Lifecycle Management Unit
  • Feb 04, 2021
    Conference on FY2020.12 Financial Results
    Review of 2020 and General Overview of IBI 21
    Tatsuro Kosaka,
    Chairman & CEO
    FY2020 Consolidated Financial Overview (Core)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Tetsuya Yamaguchi,
    Senior Vice President, Head of Project & Lifecycle Management Unit
    New Growth Strategy for 2030
    Dr. Osamu Okuda,
    President & COO

2020

  • Dec 02, 2020
    Chugai Digital Strategy Meeting
    CHUGAI DIGITAL VISION 2030
    Satoko Shisai, Vice President, Head of Digital & IT Supervisory Div.
    Innovation in the Drug Discovery Process Using AI
    Dr. Hiroyuki Tsunoda, Head of Discovery Technology Dept., Research Div.
    Utilization of Real World Data
    Dr. Nobuya Ishii, Head of Science & Technology Intelligence Dept., Project & Lifecycle Management Unit
    Digital Marketing Strategy
    Takato Shimauchi, Head of Customer Solution Dept., Marketing & Sales Div.
  • Oct 22, 2020
    3Q Results (Jan - Sep 2020) Conference Call
    FY2020 3Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Head of R&D Portfolio Management Dept.,
    Project & Lifecycle Management Unit
  • Sep 29, 2020
    Chugai ESG Meeting
    Progress in sustainability-oriented management and strategies
    Motoo Ueno, Representative Director & Deputy Chairman
    Deep-dive theme 1: Sustainability-related Indicators
    Toshiaki Itagaki, Executive Vice President & CFO
    Deep-dive theme 2: Long-term Planning
    Shigehiro Yamada, Ph.D., Head of Sustainability Dept.
    Deep-dive theme 3: Examples of Shared Value Creation
    Keiji Kono, Senior Vice President,
    In charge of External Affairs Dept. and Global Health Policy
  • Sep 14, 2020
    Information Meeting on ENSPRYNG® Subcutaneous Injection
    Product Overview of ENSPRYNG® Subcutaneous Injection 120 mg Syringe
    Katsuhiro Hara,
    ENSPRYNG® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    Current Status of the Treatment for Neuromyelitis Optica Spectrum Disorders (NMOSD) and Expectations for ENSPRYNG
    Prof. Kazuo Fujihara, M.D.
    Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine
  • Jul 27, 2020
    2Q Results (Jan - Jun 2020) Conference Call
    Aiming to Achieve the Mid-term Business Plan “IBI 21”
    - FY2020 Half Year Results -
    Tatsuro Kosaka,
    Chairman and CEO
    FY2020 2Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Minoru Watanabe,
    Vice President, Head of Project & Lifecycle Management Unit
  • Apr 23, 2020
    1Q Results (Jan - Mar 2020) Conference Call
    FY2020 1Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Head of R&D Portfolio Management Dept.,
    Project & Lifecycle Management Unit
  • Jan 30, 2020
    Media conference on FY 2019.12 Financial Results
    Mid-term Business Plan “IBI 21”
    - 2019 Results and 2020 Strategic Policies -
    Tatsuro Kosaka,
    President and CEO
    FY2019 Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Yasushi Ito,
    Executive Vice President and Co-Head of Project & Lifecycle Management Unit

2019

  • Dec 09, 2019
    Information Meeting on Antibody Engineering Technologies
    Chugai’s Strategy for Drug Discovery Research
    Junichi Nezu, PhD,
    General Manager of Research Division
    Chugai Pharmaceutical Co., Ltd.
    Chugai’s Antibody Engineering Technologies for Innovative Drug Discovery
    Tomoyuki Igawa, PhD,
    CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.
  • Oct 24,2019
    3Q Results (Jan - Sep 2019) Conference Call
    FY2019 3Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President, CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Department Manager of R&D Portfolio Management Dept
  • Sep 05, 2019
    Information Meeting on Rozlytrek®
    Product Overview of Rozlytrek®
    Yoshito Nakanishi,
    Rozlytrek® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    From organ specific to gene specific cancer treatment
    - Expectations on ROZLYTREK for NTRK Fusion-Positive Solid Tumors -
    Takayuki Yoshino, MD, PhD
    Director, Department of Gastroenterology and Gastrointestinal Oncology,
    National Cancer Center Hospital East (NCCE), Japan
    Co-principal investigator, GI-SCREEN-Japan
  • Jul 25, 2019
    Media Conference on FY2019 2Q Financial Results
    Aiming to Achieve the Mid-term Business Plan “IBI 21”
    - FY2019 Half Year Results -
    Tatsuro Kosaka,
    President and CEO
    FY2019 2Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Yasushi Ito,
    Executive Vice President and Co-Head of Project & Lifecycle Management Unit
  • Jul 04, 2019
    Information Meeting on FoudationOne® CDx
    1. FoundationOne® CDx Cancer Genomic Profile Product Overview
    Kosuke Iijima, Department Manager of Foundation Medicine Business Dept., Foundation Medicine Unit
    2. Cancer Genomic Medicine
    - Clinical Implementation and Challenges -
    Prof. Muto Manabu, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University
  • Jun 18, 2019
    ESG Meeting

    Motoo Ueno, Representative Director, Deputy Chairman

  • Apr 24, 2019
    1Q Results (Jan - Mar 2019) Conference Call
    FY2019 1Q Consolidated Financial Overview
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Department Manager of R&D Portfolio Management Dept.,
    Project & Lifecycle Management Unit
  • Jan 31, 2019
    Information Meeting on FY 2018.12 Financial Results
    New Mid-term Business Plan “IBI 21”
    Tatsuro Kosaka,
    President and CEO
    FY2018 Consolidated Financial Overview (IFRS based)
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Yasushi Ito,
    Executive Vice President and Co-Head of Project & Lifecycle Management Unit

2018

  • Nov 07, 2018
    Information Meeting on GAZYVA®
    1. Product Overview of GAZYVA® Intravenous Infusion 1000 mg
    Naoko Oya, GAZYVA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab
    Kiyohiko Hatake, M.D., Ph.D.
    Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan
  • Oct 24, 2018
    3Q Results (Jan - Sep 2018) Conference Call
    FY2018 3Q Consolidated Financial Overview (IFRS based)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Department Manager of R&D Portfolio Management Dept.,
    Project & Lifecycle Management Unit
  • Jul 26, 2018
    Media Conference on FY2018 2Q Financial Results
    Aiming to Achieve Mid-term Business Plan “IBI 18”
    - FY2018 Half Year Results -
    Tatsuro Kosaka,
    President and CEO
    FY2018 2Q Consolidated Financial Overview (IFRS based)
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Yasushi Ito,
    Executive Vice President and Co-Head of Project & Lifecycle Management Unit
  • Jun 01, 2018
    Information Meeting on HEMLIBRA®
    1. HEMLIBRA® Subcutaneous Injection Product Overview
    Hiroshi Motegi, HEMLIBRA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA®
    Prof. Midori Shima, M.D., Ph.D.
    Department of Pediatrics, Nara Medical University
  • Apr 12, 2018
    Information Meeting on TECENTRIQ®
    1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
    Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
    Hiroyoshi Nishikawa, M.D., Ph.D.
    Department of Immunology, Nagoya University Graduate School of Medicine
    Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center
    3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
    Yuichiro Ohe, M.D.
    Deputy Director, Chief,
    Division of Thoracic Oncology
    National Cancer Center Hospital, Japan
  • Feb 01, 2018
    Media Conference on 2017.12 Financial Results
    Aiming to Achieve Mid-Term Business Plan “IBI 18”
    -2017 Results and 2018 Outlook-
    Tatsuro Kosaka, President, COO
    FY2017 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito, Senior Vice President,
    Head of Project & Lifecycle Management Unit

2017

  • Oct 30, 2017
    CEO Meeting
    Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry
    Chairman and CEO Osamu Nagayama
  • Jul 27, 2017
    Media Conference on FY2017 2Q Financial Results
    FY2017 2Q Consolidated Financial Overview
    Yoshio Itaya,
    Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito,
    Senior Vice President, Head of Project & Lifecycle Management Unit
  • Feb 01, 2017
    Media Conference on 2016.12 Financial Results
    Mid-Term Business Plan “IBI 18”
    -2016 Results and 2017 Outlook-
    Tatsuro Kosaka, President, COO
    FY2016 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito, Senior Vice President,
    Head of Project & Lifecycle Management Unit
    Reorganization to Provide a New Solution
    Susumu Kato, Senior Vice President,
    General Manager of Marketing & Sales Div.

2016

  • Jul 21, 2016
    Media Conference on FY2016 2Q Financial Results
    FY2016 2Q Consolidated Financial Overview
    Yoshio Itaya,
    Executive Vice President CFO
    Overview of Development Pipeline
    Minoru Watanabe,
    Associate Vice President
    Deputy General Manager of Research Division
  • May 19, 2016
    Joint Press Conference by Osaka University and Chugai Pharmaceutical Co., Ltd.
    Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.
    Executive Vice President of Research and Risk Management, Osaka University
    Yasushi Yagi
    Outline of Comprehensive Collaboration with IFReC
    CHUGAI PHARMACEUTICAL CO., LTD.
    Executive Vice President
    Yutaka Tanaka
  • Apr 05, 2016
    Information Meeting on Bonviva®
    1. Product Overview of Bonviva® Tablet
    Takeshi Sakaguchi
    Bonviva® Product Manager
    Chugai Pharmaceutical Co., Ltd.
    2. Bonviva® Tablet: Clinical Utility and Our Expectation
    Hiroshi Hagino, M.D., Ph.D., Professor
    School of Health Science
    Tottori University Faculty of Medicine, Japan
  • Jan 28, 2016
    Media Conference on 2015.12 Financial Results
    New Mid-Term Business Plan "IBI 18"
    Tatsuro Kosaka, President, COO
    FY2015 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President

2015

  • Jul 23, 2015
    Media Conference on FY 2015.12 2Q Financial Results
    FY2015 2Q Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President
  • Apr 02, 2015
    Information Meeting on ZELBORAF®
    1. Overview of ZELBORAF®
    Takahiro Mizui
    ZELBORAF® Lifecycle Leader
    CHUGAI PHARMACEUTICAL CO., LTD.
    2. cobas® BRAF V600 Mutation Test
    Toru Ogawa
    Manager, Molecular Diagnostics
    Roche Diagnostics K.K.
    3. ZELBORAF® tablet Postmarketing safety measures
    Shin Yoshida
    Pharmacovigilance Department
    CHUGAI PHARMACEUTICAL CO., LTD.
    4.Overview of melanoma and clinical trials of vemurafenib
    Naoya Yamazaki, M.D., Ph.D.
    Chief, Dept. of Dermatologic Oncology
    National Cancer Center Hospital, Japan
  • Jan 28, 2015
    Media Conference on 2014.12 Financial Results
    Aiming to Become a Top Pharmaceutical Company
    Tatsuro Kosaka, President, COO
    FY2014 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President,
    Head of Project & Lifecycle Management Unit
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top